Johnson & Johnson Innovative Medicine have announced its strengthened commitment in Italy, with a projected investment of 580 million euros over the next five years, of which €125 million will support an increase in production capacity.
Adriano Leuzzi, Head of Process Development and Angelo Raggioli, Head of Technology Development at ReiThera explore the advancements and challenges in bioprocessing for viral-vector gene therapy manufacturing in our latest EPM Online insight.
Cycle Pharmaceuticals a rapidly growing pharmaceutical company focused on treatments for the underserved rare disease patient community, have confirmed that it made a proposal to the Board of Directors of Vanda Pharmaceuticals, Inc.
Ecolab have announced that its Purolite resin business, together with Repligen Corporation has commercially launched Purolite’s DurA Cycle, a protein A chromatography resin for large-scale purification processes.
Almac Group, the global contract pharmaceutical development and manufacturing organisation, has announced its financial results for year ending 30 September 2023.
Eli Lilly and Company have announced that it has more than doubled its investment in its Lebanon, Indiana, manufacturing site with a new $5.3 billion commitment, increasing the company's total investment in this site from $3.7 billion to $9 billion.
Johnson & Johnson have announced that it has entered into a definitive agreement to acquire Proteologix, Inc., a privately-held biotechnology company focused on bispecific antibodies for immune-mediated diseases, for $850 million.
Sanofi, Formation Bio and OpenAI are collaborating to build AI-powered software to accelerate drug development and bring new medicines to patients more efficiently.
To discuss the recent news from Exothera that the company are expand into North America, we at EPM caught up with Darren Leva, Chief Business Officer, Exothera.
Ramesh Ramani and RaviKanth Valigari, AI experts at ArisGlobal, explore how large language model-enabled AI will sharpen drug safety & regulatory practice.
Novo Holdings will acquire an approximately 60% controlling stake in Singe Use Support, alongside the two company founders who will each retain 10% and Danaher which will retain 20% of the share capital.
